<p>吉利德科学（NASDAQ:GILD - 获取免费报告）在周一发布给投资者的研究报告中，瑞银集团将其目标价从 145.00 美元上调至 155.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。瑞银集团的目标价意味着该公司股价有潜在的 12.32% 的上涨空间。</p>
<ul>
<li>3 家投资者可能希望在 2026 年之前关注的现金流机器</li>
</ul>
<p>其他一些股票研究分析师也最近对该公司发布了报告。Needham &amp; Company LLC 将吉利德科学的目标价从 133.00 美元上调至 140.00 美元，并在 11 月 13 日的研究报告中给予该公司 “买入” 评级。摩根士丹利将吉利德科学的目标价从 151.00 美元下调至 150.00 美元，并在 1 月 13 日的报告中为该公司设定了 “超配” 评级。大和资本市场将吉利德科学的目标价从 128.00 美元上调至 129.00 美元，并在 11 月 13 日的报告中给予该公司 “跑赢大盘” 评级。罗斯柴尔德与红烧（Rothschild &amp; Co Redburn）将吉利德科学的目标价从 153.00 美元上调至 159.00 美元，并在 1 月 20 日的报告中给予该股票 “买入” 评级。最后，高盛集团将吉利德科学的目标价从 110.00 美元上调至 115.00 美元，并在 1 月 8 日的研究报告中给予该公司 “中性” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，二十三位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 134.52 美元。</p>
<p>获取 <strong>吉利德科学</strong> 的提醒：</p>
<p><strong>查看我们关于吉利德科学的最新报告</strong></p>
<h2>吉利德科学股票表现</h2>
<ul>
<li>3 家将大现金流转化为更大股东收益的公司</li>
</ul>
<p>周一，GILD 的股票上涨 2.07 美元，达到 138.00 美元。该公司股票交易量为 4,102,575 股，而其平均交易量为 7,152,059 股。该股票的 50 日简单移动平均为 123.98 美元，200 日简单移动平均为 118.71 美元。该股票的市值为 1712.1 亿美元，市盈率为 21.39，市盈增长比率为 0.71，贝塔值为 0.33。吉利德科学的 52 周低点为 93.10 美元，52 周高点为 137.99 美元。该公司的流动比率为 1.45，速动比率为 1.31，债务与股本比率为 1.03。</p>
<p>吉利德科学（NASDAQ:GILD - 获取免费报告）最近在 10 月 30 日发布了季度财报。这家生物制药公司报告每股收益为 2.47 美元，超出市场共识预期的 2.16 美元，超出 0.31 美元。该公司季度收入为 77.7 亿美元，而分析师预期为 74.2 亿美元。吉利德科学的股本回报率为 51.86%，净利润率为 27.88%。该公司的收入同比增长 3.0%。在去年同期，该公司每股收益为 2.02 美元。吉利德科学已将其 2025 财年的指导目标设定为每股收益 8.050-8.250 美元。分析师预计吉利德科学在当前财年将发布每股收益 7.95 美元。</p>
<h2>吉利德科学的内部活动</h2>
<ul>
<li>5 家在行业轮动中值得关注的医疗公司</li>
</ul>
<p>在相关消息中，董事 Kelly A. Kramer 在 11 月 28 日的交易中出售了 2805 股该公司的股票。股票以 127.10 美元的平均价格出售，总价值为 356,515.50 美元。交易完成后，该董事直接持有公司 1339 股，价值约为 170,186.90 美元。此次交易使其持股减少了 67.69%。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，董事 Jeffrey Bluestone 在 1 月 20 日的交易中出售了 5000 股该公司的股票。股票以 123.50 美元的平均价格出售，总价值为 617,500.00 美元。出售后，该董事持有 8920 股，价值 1,101,620 美元。此次交易使其持股减少了 35.92%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去三个月内共出售了 141,757 股公司股票，价值 17,569,112 美元。内部人士持有该股票的比例为 0.27%。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近买入和卖出了该公司的股票。Csenge Advisory Group 在第三季度将其在吉利德科学的持股增加了 319.0%。Csenge Advisory Group 目前持有 21,394 股该生物制药公司的股票，价值 237.5 万美元，此前在该期间内又购买了 16,288 股。铁路养老金投资有限公司在第三季度将其在吉利德科学的持股增加了 3.1%。铁路养老金投资有限公司目前持有 1,415,665 股该生物制药公司的股票，价值 1.57139 亿美元，此前在该期间内又购买了 42,200 股。TriaGen Wealth Management LLC 在第三季度购买了吉利德科学的新股份，价值 1,274,000 美元。Invesco Ltd.在第二季度将其在吉利德科学的持股增加了 33.5%。Invesco Ltd.目前持有 13,521,228 股该生物制药公司的股票，价值 14.99 亿美元，此前在上个季度又收购了 3,394,330 股。最后，iA Global Asset Management Inc.在第三季度将其在吉利德科学的持股增加了 11.6%。iA Global Asset Management Inc.目前持有 221,890 股该生物制药公司的股票，价值 2463 万美元，此前在上个季度又购买了 23,046 股。对冲基金和其他机构投资者持有该公司 83.67% 的股票。</p>
<h2>关于吉利德科学</h2>
<p>（获取免费报告）</p>
<p>吉利德科学公司成立于 1987 年，总部位于加利福尼亚州福斯特城，是一家专注于高未满足医疗需求领域药物发现、开发和商业化的生物制药公司。该公司最初在抗病毒疗法方面建立了声誉，随后扩展到肿瘤学、细胞治疗和炎症性疾病。吉利德在全球范围内运营研究和商业组织，进行临床开发并在全球市场销售药物。</p>
<p>吉利德的产品组合以抗病毒疗法为基础，主要针对 HIV 和病毒性肝炎。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>你的签名缺失 - 在为时已晚之前采取行动</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>崩盘前一个月</li>
<li>没有人告诉你的 100 万亿美金的人工智能故事</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在吉利德科学吗？</h2>
<p>在考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IBBQ

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

<p>瑞士银行集团将吉利德科学（NASDAQ:GILD）的目标股价从 145.00 美元上调至 155.00 美元，维持 “买入” 评级。这表明与前一交易日收盘价相比，潜在上涨幅度为 12.32%。其他分析师也调整了他们的目标，平均评级为 “适度买入”，目标股价为 134.52 美元。吉利德的股票最近交易价格为 138.00 美元，市值为 1712.1 亿美元。该公司报告每股收益为 2.47 美元，超出预期，并已将 2025 财年的指导目标设定为每股收益 8.050-8.250 美元</p>

<p>Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target upped by research analysts at UBS Group from $145.00 to $155.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. UBS Group's price objective would indicate a potential upside of 12.32% from the company's previous close.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）在周一发布给投资者的研究报告中，瑞银集团将其目标价从 145.00 美元上调至 155.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。瑞银集团的目标价意味着该公司股价有潜在的 12.32% 的上涨空间。</p>
</div><ul>
<li>3 Cash-Flow Machines Investors May Want Heading Into 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家投资者可能希望在 2026 年之前关注的现金流机器</li>
</ul>
</div><p>A number of other equities research analysts have also recently issued reports on the company. Needham &amp; Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, January 13th. Daiwa Capital Markets boosted their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 13th. Rothschild &amp; Co Redburn raised their price target on Gilead Sciences from $153.00 to $159.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, January 20th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $134.52.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也最近对该公司发布了报告。Needham &amp; Company LLC 将吉利德科学的目标价从 133.00 美元上调至 140.00 美元，并在 11 月 13 日的研究报告中给予该公司 “买入” 评级。摩根士丹利将吉利德科学的目标价从 151.00 美元下调至 150.00 美元，并在 1 月 13 日的报告中为该公司设定了 “超配” 评级。大和资本市场将吉利德科学的目标价从 128.00 美元上调至 129.00 美元，并在 11 月 13 日的报告中给予该公司 “跑赢大盘” 评级。罗斯柴尔德与红烧（Rothschild &amp; Co Redburn）将吉利德科学的目标价从 153.00 美元上调至 159.00 美元，并在 1 月 20 日的报告中给予该股票 “买入” 评级。最后，高盛集团将吉利德科学的目标价从 110.00 美元上调至 115.00 美元，并在 1 月 8 日的研究报告中给予该公司 “中性” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，二十三位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 134.52 美元。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>吉利德科学</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on Gilead Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于吉利德科学的最新报告</strong></p>
</div><h2>Gilead Sciences Stock Performance</h2>
<div class="lb-trans"><h2>吉利德科学股票表现</h2>
</div><ul>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家将大现金流转化为更大股东收益的公司</li>
</ul>
</div><p>Shares of GILD traded up $2.07 on Monday, reaching $138.00. 4,102,575 shares of the company's stock traded hands, compared to its average volume of 7,152,059. The stock's 50 day simple moving average is $123.98 and its two-hundred day simple moving average is $118.71. The stock has a market cap of $171.21 billion, a PE ratio of 21.39, a PEG ratio of 0.71 and a beta of 0.33. Gilead Sciences has a 52-week low of $93.10 and a 52-week high of $137.99. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.</p>
<div class="lb-trans"><p>周一，GILD 的股票上涨 2.07 美元，达到 138.00 美元。该公司股票交易量为 4,102,575 股，而其平均交易量为 7,152,059 股。该股票的 50 日简单移动平均为 123.98 美元，200 日简单移动平均为 118.71 美元。该股票的市值为 1712.1 亿美元，市盈率为 21.39，市盈增长比率为 0.71，贝塔值为 0.33。吉利德科学的 52 周低点为 93.10 美元，52 周高点为 137.99 美元。该公司的流动比率为 1.45，速动比率为 1.31，债务与股本比率为 1.03。</p>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts' expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business's revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）最近在 10 月 30 日发布了季度财报。这家生物制药公司报告每股收益为 2.47 美元，超出市场共识预期的 2.16 美元，超出 0.31 美元。该公司季度收入为 77.7 亿美元，而分析师预期为 74.2 亿美元。吉利德科学的股本回报率为 51.86%，净利润率为 27.88%。该公司的收入同比增长 3.0%。在去年同期，该公司每股收益为 2.02 美元。吉利德科学已将其 2025 财年的指导目标设定为每股收益 8.050-8.250 美元。分析师预计吉利德科学在当前财年将发布每股收益 7.95 美元。</p>
</div><h2>Insider Activity at Gilead Sciences</h2>
<div class="lb-trans"><h2>吉利德科学的内部活动</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家在行业轮动中值得关注的医疗公司</li>
</ul>
</div><p>In related news, Director Kelly A. Kramer sold 2,805 shares of the company's stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 141,757 shares of company stock worth $17,569,112 in the last three months. 0.27% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Kelly A. Kramer 在 11 月 28 日的交易中出售了 2805 股该公司的股票。股票以 127.10 美元的平均价格出售，总价值为 356,515.50 美元。交易完成后，该董事直接持有公司 1339 股，价值约为 170,186.90 美元。此次交易使其持股减少了 67.69%。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，董事 Jeffrey Bluestone 在 1 月 20 日的交易中出售了 5000 股该公司的股票。股票以 123.50 美元的平均价格出售，总价值为 617,500.00 美元。出售后，该董事持有 8920 股，价值 1,101,620 美元。此次交易使其持股减少了 35.92%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去三个月内共出售了 141,757 股公司股票，价值 17,569,112 美元。内部人士持有该股票的比例为 0.27%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the business. Csenge Advisory Group boosted its position in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock worth $2,375,000 after purchasing an additional 16,288 shares during the period. Railway Pension Investments Ltd boosted its holdings in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock worth $157,139,000 after buying an additional 42,200 shares during the period. TriaGen Wealth Management LLC purchased a new stake in Gilead Sciences in the 3rd quarter worth $1,274,000. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company's stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. Finally, iA Global Asset Management Inc. grew its position in shares of Gilead Sciences by 11.6% during the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company's stock worth $24,630,000 after purchasing an additional 23,046 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了该公司的股票。Csenge Advisory Group 在第三季度将其在吉利德科学的持股增加了 319.0%。Csenge Advisory Group 目前持有 21,394 股该生物制药公司的股票，价值 237.5 万美元，此前在该期间内又购买了 16,288 股。铁路养老金投资有限公司在第三季度将其在吉利德科学的持股增加了 3.1%。铁路养老金投资有限公司目前持有 1,415,665 股该生物制药公司的股票，价值 1.57139 亿美元，此前在该期间内又购买了 42,200 股。TriaGen Wealth Management LLC 在第三季度购买了吉利德科学的新股份，价值 1,274,000 美元。Invesco Ltd.在第二季度将其在吉利德科学的持股增加了 33.5%。Invesco Ltd.目前持有 13,521,228 股该生物制药公司的股票，价值 14.99 亿美元，此前在上个季度又收购了 3,394,330 股。最后，iA Global Asset Management Inc.在第三季度将其在吉利德科学的持股增加了 11.6%。iA Global Asset Management Inc.目前持有 221,890 股该生物制药公司的股票，价值 2463 万美元，此前在上个季度又购买了 23,046 股。对冲基金和其他机构投资者持有该公司 83.67% 的股票。</p>
</div><h2>About Gilead Sciences</h2>
<div class="lb-trans"><h2>关于吉利德科学</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.</p>
<div class="lb-trans"><p>吉利德科学公司成立于 1987 年，总部位于加利福尼亚州福斯特城，是一家专注于高未满足医疗需求领域药物发现、开发和商业化的生物制药公司。该公司最初在抗病毒疗法方面建立了声誉，随后扩展到肿瘤学、细胞治疗和炎症性疾病。吉利德在全球范围内运营研究和商业组织，进行临床开发并在全球市场销售药物。</p>
</div><p>Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.</p>
<div class="lb-trans"><p>吉利德的产品组合以抗病毒疗法为基础，主要针对 HIV 和病毒性肝炎。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>A month before the crash</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>你的签名缺失 - 在为时已晚之前采取行动</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>崩盘前一个月</li>
<li>没有人告诉你的 100 万亿美金的人工智能故事</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $155.00

Market Beat

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

基因改革 ETF - ARK

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

吉利德科学

动态生物技术与基因组 ETF - Invesco

吉利德科学（NASDAQ:GILD）的目标股价被上调至 155.00 美元